Loss of TXNIP expression has been reported to correlate with more aggressive disease, advanced stage, and poorer prognosis in breast, gastric, colorectal, and bladder cancers, as well as diffuse large B-cell lymphoma [23,24,42-47], and TXNIP mRNA expression has been shown to be inversely proportional to melanoma progression [27]. Here, TXNIP is linked to urinary bladder carcinoma.